Features Dyslipidemias Disorders in Patients With Schizophrenia Treated With Haloperidol and Risperidone, Depending on the Carrier State of Some Genetic Polymorphisms

Abstract

Objective – to determine the role of polymorphism of some genes in the development of dyslipidemic disorders in psychopharmacotherapy in patients with paranoid schizophrenia.
Materials and methods: 80 patients with first episode paranoid schizophrenia and 70 healthy individuals.
Research methods: molecular genetic, biochemical, statistical.
Results: it was found that carriers of the genotype Gln/Gln polymorphism Arg223Gln of the LEPR gene predominate among patients. Have been identified the risks of developing dyslipidemias
disorders in carriers of the mutant allele A of gene polymorphism АРОА1 and allele G of gene АРОС3 in schizophrenic patients. It was revealed that in the carriers of these alleles the risks
of development of dyslipidemic disorders increase during antipsychotic therapy.
Conclusions: at the beginning of paranoid schizophrenia, the risk of development of dyslipidemic disorders in carriers of different genotypes of AROA-1 and AROS3 genes was revealed. In
addition, a group of genetically vulnerable individuals with respect to lipid metabolism disorders against the background of receiving antipsychotics was established.